Worldwide Views on SGLT2 Inhibitors to Optimize Glucose Homeostasis in Type 2 Diabetes Mellitus: Interactive Patient Case Study

Axis SGLT2
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
November 02, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Endocrinologists, primary care physicians, scientists, and other healthcare professionals who manage the care of patients with type 2 diabetes mellitus

Relevant Terms:

Type 2 Diabetes

Anne L. Peters, MD

Anne L. Peters, MD
Keck School of Medicine
University of Southern California
Los Angeles, California

Anne L. Peters, MD, is a professor at the Keck School of Medicine of the University of Southern California and the Director of the USC Clinical Diabetes Programs.  Dr. Peters has been a principal investigator on multiple clinical trials focusing on diabetes and diabetes prevention. She established the Community Diabetes Initiatives Research Center in collaboration with Children's Hospital Los Angeles with funding from the Keck Foundation, the JDRF, ADA, California Nutrition Network and Helmsley Trust.  Dr. Peters is a Principal Investigator for the NIH Look AHEAD Study and the UCLA/USC NIH P50 program project, "Family and Neighborhood Interventions to Reduce Heart Disease Risk in East L.A."
She has been an invited speaker at many local, national and international medical conferences.  Dr. Peters has authored three books on diabetes and over 100 articles appearing in peer-reviewed medical journals, including JAMA, Annals of Internal Medicine, Archives of Internal Medicine, Diabetes Care and the American Journal of Medicine.  She serves on the ABIM Endocrine Board and the Board of the ADA.  Dr. Peters received the ADA Outstanding Physician Clinician Award in 2008 and the 2010 Bernardo Houssay Award from the National Minority Quality Forum for her work with the underserved. She was a member of the type 2 diabetes treatment working group and is an author of the "ADA/EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes" and the ADA Position Statement on Transitioning Youth.  Dr. Peters earned her undergraduate degree from Wesleyan University in Middletown, Conn., and her medical degree from the Pritzker School of Medicine at the University of Chicago.
1. Review the role of the kidney in blood glucose regulation in type 2 diabetes mellitus
2. Validate the rationale for SGLT2 inhibitor therapy based on its unique glycosuria-based mechanism of action
3. Determine the appropriate use of SGLT2 therapy in patients with type 2 diabetes that are otherwise healthy or exhibit higher blood glucose concentration
4. Integrate emerging evidence on novel SGLT2 inhibitors into the treatment paradigm for patients with type 2 diabetes mellitus

The goal for this program is to begin to close educational and practice gaps by providing clinicians with the latest clinical evidence on the appropriate use of SGLT2 inhibitors, as well as benefits and risks to optimize glycemic control throughout type 2 diabetes mellitus care continuum.
Accreditation Statement
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
Credit Designation
Endocrine Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Independence
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
Policy on Unlabeled/Off-Labeled Use
Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.
Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above